Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Retained Earnings (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Retained Earnings for 11 consecutive years, with -$457.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 3.23% to -$457.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$457.5 million, a 3.23% decrease, with the full-year FY2024 number at -$447.0 million, down 2.46% from a year prior.
  • Retained Earnings was -$457.5 million for Q3 2025 at Marker Therapeutics, roughly flat from -$455.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$365.0 million in Q1 2021 to a low of -$457.5 million in Q3 2025.
  • A 5-year average of -$424.9 million and a median of -$433.0 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: fell 11.78% in 2022, then dropped 1.31% in 2024.
  • Marker Therapeutics' Retained Earnings stood at -$398.1 million in 2021, then decreased by 7.52% to -$428.0 million in 2022, then fell by 1.92% to -$436.3 million in 2023, then fell by 2.46% to -$447.0 million in 2024, then fell by 2.34% to -$457.5 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Retained Earnings are -$457.5 million (Q3 2025), -$455.5 million (Q2 2025), and -$451.5 million (Q1 2025).